ACT

Accelerated Clinical Trials (ACT) is an enterprise agentic AI workflow platform developed by ConcertAI, designed to streamline and automate the end-to-end clinical trial process. By integrating real-world and proprietary data with advanced AI workflows, ACT accelerates key activities including study design, feasibility analysis, site selection, patient recruitment, and operational monitoring. The platform is built for life sciences organizations seeking to bring therapies to market faster while reducing costs and improving decision-making quality.

ACT delivers measurable improvements across every stage of the trial lifecycle: organizations can expect trial timelines shortened by 20 or more months, operational costs reduced by 20%, costly protocol amendments cut by 50%, and site activation accelerated by approximately 60 days. These outcomes translate directly into competitive advantage and significant savings across each study iteration.

Key Benefits

• Accelerated time to market: AI-powered tools including Design, Feasibility, and Writing Assistants cut study design and protocol development timelines by up to 50%, while real-time monitoring and centralized workflows reduce overall trial durations by 6–19 months.
• Improved likelihood of success: Advanced predictive modeling delivers highly accurate probability forecasts, improving trial success rates by up to 30% compared to traditional estimation methods and enabling proactive adjustments to enhance outcomes.
• Significant cost savings: Optimized study design and feasibility validation reduce costly amendments by up to 50%, while streamlined site validation and data integration minimize errors, saving millions in operational costs per trial.
• Competitive advantage: ACT's Competitive Trial Agent analyzes and compares study design parameters, and ConcertAI's CARAai platform delivers tailored insights. ConcertAI has been recognized as a top Clinical Trial AI vendor for 2026 by Frost & Sullivan.

Core Capabilities

• Cohort Creation & Optimization: Translates protocol criteria into real-world patient cohorts using AI tools and curated data to assess feasibility and optimize patient selection early in the process.
• Study Design Optimization: Optimizes protocols with predictive AI, mitigates amendment risks, and aligns designs with real-world data and standards of care, saving $1–6 million per trial.
• Site Selection Optimization: Prioritizes high-performing sites using AI-driven tools, reducing non-productive sites by 25% and shortening site activation timelines by 1–2 months.
• Site Start-up & Activation: Automates trial documentation revisions to reduce delays, enhances site activation timelines with AI-driven workflows, and simplifies contract and regulatory processes for faster start-up.
• Study Management & Monitoring: Monitors site performance and alignment with trial goals, generates automated remediation strategies for underperforming sites, and provides real-time insights to mitigate operational risks.

CARAai-Powered Assistants and Agents

• ACT is built on ConcertAI's real-world data foundation and powered by CARAai, purpose-built for enterprise clinical development and operations.
• Key Assistants handle trial design, feasibility analysis, recruitment, and documentation workflows.
• Advanced Agents optimize inclusion/exclusion criteria, site validation, and enrollment predictions.
• This integrated system of Assistants and Agents accelerates the full clinical trial lifecycle from protocol conception through study close-out.

Industry Recognition and Partnerships

• ConcertAI leads oncology trials with AI-driven tools like CARAai, optimizing recruitment and workflows across the clinical research landscape.
• The Precision Suite and ACT tools cement ConcertAI's role in transforming clinical research with AI innovation.
• Strategic partnerships with Bayer, NVIDIA, and others drive growth, expand site networks, and advance precision medicine initiatives.
• ConcertAI's vast real-world data database and AI models are designed to ensure diversity, inclusion, and global impact in clinical trials.

ACT is deployed as an enterprise platform integrating ConcertAI's proprietary real-world data assets with AI-driven workflows, making it suitable for pharmaceutical and biotech organizations managing complex, large-scale clinical development programs. The platform's agentic architecture enables continuous optimization across recruitment forecasting, site performance, and protocol management throughout the trial lifecycle.